A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)

被引：3
|
作者：
Rathkopf, D. E.
Wong, B. Y.
Ross, R. W.
George, D. J.
Picus, J.
Tanaka, E.
Chen, Y.
Atadja, P.
Yang, W.
Culver, K. W.
Scher, H. I.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Nevada Canc Inst, Las Vegas, NV USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Washington Univ, St Louis, MO USA
[6] Novartis Inst Biomed Res, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5152
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer
    Mardjuadi, F.
    Medioni, J.
    Kerger, J.
    Canon, J. L.
    Duck, L.
    Oudard, S.
    Clausse, M.
    D'Hondt, L.
    Moxhon, A.
    Machiels, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer
    Feby Mardjuadi
    Jacques Medioni
    Joseph Kerger
    Lionel D’Hondt
    Jean-Luc Canon
    Lionel Duck
    Flora Musuamba
    Stephane Oudard
    Marylene Clausse
    Anne Moxhon
    Jean-Pascal Machiels
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 293 - 303
  • [23] Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-na⟨ve patients with metastatic castration-resistant prostate cancer
    Mardjuadi, Feby
    Medioni, Jacques
    Kerger, Joseph
    D'Hondt, Lionel
    Canon, Jean-Luc
    Duck, Lionel
    Musuamba, Flora
    Oudard, Stephane
    Clausse, Marylene
    Moxhon, Anne
    Machiels, Jean-Pascal
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 293 - 303
  • [24] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
    Courtney, Kevin D.
    Manola, Judith B.
    Elfiky, Aymen A.
    Ross, Robert
    Oh, William K.
    Yap, Jeffrey T.
    Van den Abbeele, Annick D.
    Ryan, Christopher W.
    Beer, Tomasz M.
    Loda, Massimo
    Priolo, Carmen
    Kantoff, Philip
    Taplin, Mary-Ellen
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
  • [25] The Safety and Tolerability of Panobinostat (LBH589) in Combination with Capecitabine plus /- Lapatinib: A Phase I Study in HER2+Breast Cancer
    Peacock, N. W.
    Jones, S. F.
    Yardley, D. A.
    Bendel, J. C.
    Infante, J. R.
    Murphy, P. B.
    Burns, H. A.
    CANCER RESEARCH, 2010, 70
  • [26] Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
    Veccia, A.
    Caffo, O.
    Brugnara, S.
    Caldara, A.
    di Pasquale, M. C.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Pappagallo, G. L.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    van Dodewaard-de Jong, Joyce M.
    de Klerk, John M. H.
    Bloemendal, Haiko J.
    Oprea-Lager, Daniela E.
    Hoekstra, Otto S.
    van den Berg, H. Pieter
    Los, Maartje
    Beeker, Aart
    Jonker, Marianne A.
    O'Sullivan, Joe M.
    Verheul, Henk M. W.
    van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (08) : 1319 - 1327
  • [28] A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial
    Joyce M. van Dodewaard-de Jong
    John M. H. de Klerk
    Haiko J. Bloemendal
    Daniela E. Oprea-Lager
    Otto S. Hoekstra
    H. Pieter van den Berg
    Maartje Los
    Aart Beeker
    Marianne A. Jonker
    Joe M. O’Sullivan
    Henk M. W. Verheul
    Alfons J. M. van den Eertwegh
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1319 - 1327
  • [29] LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC.
    Ferrari, Anna C.
    Alumkal, Joshi J.
    Stein, Mark N.
    Mayer, Tina M.
    Torneten, Sarah
    Babb, James
    Taplin, Mary-Ellen
    DiPaola, Robert S.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
12345